Results 271 to 280 of about 817,279 (353)

LncRNA Foxo6os as a Novel “ Scaffold” Mediates MYBPC3 in Combating Pathological Cardiac Hypertrophy and Heart Failure

Advanced Science, EarlyView.
Schematic overview showing that forkhead box O6, opposite strand (Foxo6os) acts as a “scaffold”, directly binding myosin‐binding protein‐C (MYBPC3) and recruiting protein kinase C (PKC‐α) to mediate site‐specific phosphorylation of MYBPC3. This post‐translational modification supports cardiac contraction by regulating L‐type Ca2+ channels, especially ...
Jie Sheng, Qin Lin, Yizhuo Sun, Yilei Meng, Sangyu Hu, Huaming Cao, Fang Lin, Yuping Zhu, Luying Peng, Li Li   +9 more
wiley   +1 more source

Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary Thyroid Cancer. [PDF]

NPJ Precis Oncol
Rix B, Chauhan R, Masoumi Z, Grönroos E, Brain CE, Ogunbiyi OK, Swarbrick K, Swanton C, Bonnet D, Kurzawinski TR, Izatt L, McDonald NQ, Grey W.   +12 more
europepmc   +1 more source

Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver Metastases

Advanced Science, EarlyView.
This study synthesized a personalized neoantigen vaccine (Neo‐CRCVAS) and combined it with regorafenib, termed RegoNeo. This combination therapy significantly enhanced antitumor efficacy and promoted long‐term tumor‐specific immune memory in microsatellite stable colorectal cancer liver metastasis (MSS‐CRLM) models by increasing neoantigen‐specific ...
Hengkai Chen, Bin Chen, Yuanfeng Yang, Shoufeng Li, Huajun Cai, Zhicheng Zhuang, Yong Wu, Yuan Gao, Yupeng Chen, Xing Liu, Guoxian Guan, Jinfu Zhuang   +11 more
wiley   +1 more source

Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. [PDF]

Research (Wash D C)
Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, Deng X, Xie J, Tang H.   +8 more
europepmc   +1 more source

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Novel kinase-activating genetic events in non-small cell lung carcinomas. [PDF]

Explor Target Antitumor Ther
Preobrazhenskaya EV, Mulkidjan RS, Zagrebin FA, Romanko AA, Saitova ES, Korzun PR, Binnatova JO, Tiurin VI, Bizin IV, Imyanitov EN.   +9 more
europepmc   +1 more source

Substituted Triazole-3,5-Diamine Compounds as Novel Human Topoisomerase III Beta Inhibitors. [PDF]

Int J Mol Sci
Mamun Y, Chadni SH, Rayala R, Shafi H, Ferdous S, Pokhrel R, Nefzi A, Chapagain P, Tse-Dinh YC.   +8 more
europepmc   +1 more source

The p130Cas-Crk/CrkL Axis: A Therapeutic Target for Invasive Cancers Unveiled by Collaboration Among p130Cas, Crk, and CrkL. [PDF]

Int J Mol Sci
Farhadi P, Park T.
europepmc   +1 more source

Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm. [PDF]

Exp Ther Med
Choi Y, Lee H, Beck BR, Lee B, Lee JH, Kim S, Chun SH, Won HS, Ko YH.   +8 more
europepmc   +1 more source

Dual Inhibition of SRC Family Kinases and Sorafenib Enhances Anti-Tumor Activity in Hepatocellular Carcinoma Cells. [PDF]

Int J Mol Sci
Cabral LK, Disoma C, Tarchi P, El-Khobar KE, Agustiningsih A, Dituri F, Tiribelli C, Sukowati C.   +7 more
europepmc   +1 more source